Cribriform carcinoma of the breast — a rare and morphologically distinctive low-grade invasive breast cancer subtype accounting for approximately 1–3% of all invasive breast cancers in the United States (with pure cribriform carcinoma — defined by >90% cribriform architectural pattern — comprising a small subset of this range, and mixed cribriform carcinoma incorporating cribriform histology alongside other invasive patterns such as tubular carcinoma in a substantial proportion of cases meeting the broader cribriform carcinoma diagnostic criteria), defined by the presence of invasive tumor cells arranged in a sieve-like or fenestrated cribriform pattern (irregular spaces or pseudolumens punched out of solid nests of cells, giving the characteristic riddled or perforated appearance that names the histologic subtype), with low-grade nuclear features (Grade 1 nuclei, uniform small-to-medium nuclei with inconspicuous nucleoli and absent or rare mitoses), and an overall morphologic appearance that — when pure — overlaps substantially with in situ cribriform ductal carcinoma in situ (cribriform DCIS), necessitating careful distinction between in situ and invasive cribriform architecture that depends on the absence of a myoepithelial cell layer around the invasive nests (confirmed by p63, calponin, or SMA immunohistochemistry), occurring predominantly in postmenopausal women (median age at diagnosis in the 60s, though the age range is broad), characterized by almost universally estrogen receptor-positive and progesterone receptor-positive pathology (>90% of pure cribriform carcinomas express ER, reflecting the luminal A molecular subtype that underlies cribriform carcinoma's indolent behavior), consistently HER2-negative (HER2 amplification or overexpression documented in fewer than 5% of pure cribriform carcinomas), Grade 1 histologic classification by modified Bloom-Richardson criteria in most pure cribriform cases (the low nuclear grade and low mitotic activity generating the lowest Nottingham grade category, though mixed cribriform carcinomas incorporating ductal NOS components may grade higher depending on the non-cribriform component's nuclear grade and mitotic rate), low Ki-67 proliferation index (typically <10–15% for pure cribriform, consistent with the low-proliferation luminal A biology that characterizes its excellent prognosis), low axillary lymph node involvement (sentinel lymph node positivity in approximately 5–15% of pure cribriform carcinomas, with the mixed cribriform-tubular variant having even lower nodal involvement rates approaching those of pure tubular carcinoma), and an excellent long-term prognosis that places cribriform carcinoma among the most favorable invasive breast cancer subtypes (5-year overall survival exceeding 90–95% for pure cribriform carcinoma, 10-year survival remaining excellent, with disease-specific mortality rates approaching those of age-matched controls without breast cancer in some studies). Management closely follows the algorithm for low-grade ER-positive breast cancer: breast conservation surgery with negative margins (lumpectomy is standard for most pure and mixed cribriform carcinomas; mastectomy reserved for multifocal disease, large tumors, or patient preference), sentinel lymph node biopsy, adjuvant radiation therapy after breast conservation, genomic risk stratification with multigene assays (Oncotype DX Recurrence Score typically returns low-risk values [RS <18] for pure cribriform carcinoma given its Grade 1, low-Ki-67, ER-positive biology — confirming endocrine therapy alone is sufficient for most patients, with mixed cribriform carcinomas incorporating higher-grade non-cribriform components potentially generating intermediate RS scores that warrant individualized chemotherapy discussion), and long-term adjuvant endocrine therapy (5–10 years of tamoxifen or aromatase inhibitors as the primary systemic adjuvant therapy, with bone density monitoring during aromatase inhibitor therapy and extended therapy consideration at the 5-year decision point) — with adjuvant chemotherapy rarely if ever indicated for pure cribriform carcinoma given the consistent low-risk genomic profiles and excellent prognosis, and reserved only for mixed cribriform carcinomas with higher-grade components, intermediate-to-high Oncotype DX scores, or higher-risk pathologic features.
Cribriform carcinoma of the breast technology platforms — whether supporting Oncotype DX and genomic assay result routing platforms (coordinating genomic assay specimen submission from pure versus mixed cribriform carcinoma, tracking result turnaround, routing RS scores to the multidisciplinary team with the histologic subtype context needed to interpret the score [pure cribriform with low RS: endocrine therapy alone; mixed cribriform with intermediate RS: individualized chemotherapy discussion], and documenting the chemotherapy omission or recommendation decision with the genomic and histologic evidence basis), mixed histology documentation platforms (managing the pathologic differentiation between pure cribriform [>90% cribriform pattern], mixed cribriform-tubular [the most common mixed variant, combining two low-grade patterns both associated with excellent prognosis], and mixed cribriform-ductal NOS [incorporating higher-grade invasive ductal components whose proportion influences genomic risk score and prognosis], with structured percentage-by-histologic-component documentation enabling accurate risk stratification and treatment planning), endocrine therapy adherence dashboards (coordinating 5–10 year tamoxifen or aromatase inhibitor prescribing with refill adherence monitoring, side effect documentation, and extended therapy decision records across the decade-long treatment arc), and surveillance mammography and MRI interval scheduling platforms (managing the imaging surveillance intervals appropriate for cribriform carcinoma's indolent biology — annual mammography as the standard surveillance imaging, with breast MRI reserved for higher-risk patients including those with dense breast tissue or prior close margins, and extended surveillance scheduling across the follow-up arc appropriate for cribriform carcinoma's late recurrence risk profile) — must maintain the availability and performance standards that cribriform carcinoma's genomic assay result routing, mixed histology documentation precision, endocrine therapy adherence monitoring obligations, and surveillance scheduling demands require. This guide explains why cribriform carcinoma tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the genomic risk stratification complexity, histologic subtype documentation precision, endocrine therapy adherence duration, and surveillance scheduling demands of modern cribriform carcinoma of the breast care.
Why Cribriform Carcinoma of the Breast Tech Platforms Require Specialized Monitoring Attention
Cribriform carcinoma of the breast management is defined by the genomic assay result routing workflow where Oncotype DX Recurrence Score interpretation depends critically on whether the tumor is pure versus mixed cribriform (with pure cribriform expected to return low RS scores confirming endocrine therapy alone, while mixed cribriform with higher-grade non-cribriform components may generate intermediate or higher RS scores requiring individualized chemotherapy discussion), the mixed histology documentation complexity that distinguishes the pure cribriform and cribriform-tubular variants (where both components are low-grade and the prognosis is uniformly excellent) from mixed cribriform carcinomas incorporating ductal NOS components (where the non-cribriform component's grade may drive a higher RS score and worse prognosis), the long-term endocrine therapy adherence obligation spanning 5–10 years (where the primary treatment challenge is adherence maintenance rather than chemotherapy selection in most pure cribriform cases), and the surveillance scheduling infrastructure that must persist through the extended endocrine therapy arc and beyond. Technology failures in these domains create disruptions calibrated to the genomic risk stratification complexity, histologic documentation precision, adherence monitoring horizon, and surveillance scheduling demands of cribriform carcinoma of the breast.
Oncotype DX result routing platforms must integrate histologic subtype context. Genomic risk stratification for cribriform carcinoma — where pure cribriform carcinoma's Grade 1, low-Ki-67, ER-positive pathology consistently generates low Oncotype DX Recurrence Scores (RS <18 in the large majority of pure cribriform cases), where the RS result confirms endocrine-therapy-only management per TAILORx evidence and documents the chemotherapy omission rationale, where mixed cribriform carcinomas with higher-grade non-cribriform components (invasive ductal NOS with Grade 2 or Grade 3 features) may generate intermediate RS scores (16–25) that trigger individualized chemotherapy discussion (particularly for premenopausal women ≤50 per TAILORx subgroup analysis), where the histologic percentage documentation must accompany the RS result to permit accurate interpretation (a 20% Grade 2 ductal NOS component in a mixed cribriform tumor explains an intermediate RS result and guides the chemotherapy discussion differently than a 5% Grade 2 component in an otherwise pure cribriform tumor), and where result routing delays create patient and oncologist uncertainty during the adjuvant planning window — requires platforms managing specimen submission, result turnaround tracking, RS score delivery with histologic context annotation, and chemotherapy decision documentation. Monitor Oncotype DX result routing platforms at 1-minute intervals during business hours. Alert immediately — genomic assay routing failures delay the RS score delivery that, with histologic subtype documentation, determines chemotherapy indication in cribriform carcinoma.
Mixed histology documentation platforms determine risk stratification accuracy. Histologic subtype documentation for cribriform carcinoma — where the pathologist's documentation of the percentage and grade of each invasive component (cribriform, tubular, ductal NOS, or other) in mixed cribriform carcinomas determines which risk stratification algorithm applies, where pure cribriform (>90% cribriform pattern) consistently carries an excellent prognosis and supports chemotherapy omission independent of RS score for RS <18, where mixed cribriform-tubular carcinoma (the most favorable mixed variant, combining two Grade 1 low-grade patterns) similarly supports endocrine therapy alone, where mixed cribriform carcinoma with ductal NOS components (especially Grade 2 or Grade 3 ductal NOS comprising >20–30% of the tumor) requires more careful RS-guided chemotherapy discussion, where pathology reporting inconsistencies in cribriform component percentage documentation lead to risk stratification errors (underreporting the non-cribriform component percentage may inappropriately apply the pure cribriform favorable prognosis to a mixed tumor with substantial higher-grade components), and where multidisciplinary tumor board discussion of cribriform component percentages requires the pathology report to be linked to the genomic assay result and the treatment planning record — requires platforms managing structured percentage-by-component pathology reporting, linkage of histologic component documentation to Oncotype DX results, and multidisciplinary tumor board discussion records. Monitor mixed histology documentation platforms at 1-minute intervals during business hours. Alert immediately — pathology documentation platform failures create risk stratification gaps that may misapply pure cribriform management algorithms to mixed carcinomas requiring individualized chemotherapy assessment.
Endocrine therapy adherence dashboards sustain the primary recurrence prevention strategy. Long-term endocrine therapy management for cribriform carcinoma — where 5–10 years of tamoxifen or aromatase inhibitor therapy represents the primary adjuvant systemic intervention for the near-universal ER-positive biology of cribriform carcinoma, where prescription refill adherence monitoring with outreach for gaps >30 days is essential given the 50% community-setting discontinuation rate before 5 years in ER-positive breast cancer, where aromatase inhibitor arthralgia documentation and AI switching or AI-to-tamoxifen transition records preserve endocrine therapy continuation when intolerable musculoskeletal side effects occur, where the 5-year extended therapy decision must be documented with comorbidity assessment and tolerability record, and where the decade-long adherence obligation creates a monitoring infrastructure requirement that substantially exceeds the acute-care episode — requires platforms managing multi-year prescribing records, refill adherence tracking, side effect documentation, and extended therapy decision documentation. Monitor endocrine therapy adherence platforms at 1-minute intervals during business hours. Alert immediately — adherence platform failures disrupt the multi-year endocrine therapy monitoring that constitutes the primary recurrence prevention strategy for cribriform carcinoma.
What to Monitor on a Cribriform Carcinoma of the Breast Tech Platform
Oncotype DX / Genomic Assay Result Routing with Histologic Context
Monitor tumor tissue submission records to Genomic Health for Oncotype DX Recurrence Score analysis with histologic subtype annotation (pure cribriform vs. mixed cribriform with component percentages), specimen tracking from surgical pathology block to laboratory receipt, result turnaround time tracking (target 10–14 business days from specimen receipt), RS score delivery to medical oncologist with histologic component percentage context, TAILORx-guided interpretation documentation noting the histologic subtype modifier (pure cribriform RS <18: endocrine alone; mixed with higher-grade components RS 16–25: individualized discussion per TAILORx premenopausal ≤50 subgroup), alternative genomic assay routing (Prosigna, EndoPredict, MammaPrint) when Oncotype DX is not performed, and RS result integration with complete pathology (cribriform component percentage, tubular component percentage, NOS component grade and percentage, Ki-67, ER/PR) for comprehensive risk characterization at 1-minute intervals during result delivery windows. Alert immediately — genomic assay routing failures delay the RS score delivery that determines chemotherapy indication for mixed cribriform carcinomas.
Mixed Histology Documentation and Pure vs. Mixed Classification
Monitor structured pathology report documentation of invasive cribriform component percentage, documentation of all non-cribriform invasive component types and percentages (tubular, ductal NOS, other), nuclear grade and mitotic rate for each invasive component, pure versus mixed cribriform classification documentation (>90% cribriform = pure; ≤90% cribriform = mixed with specified component breakdown), immunohistochemical documentation of absent myoepithelial layer in invasive nests (distinguishing invasive cribriform from cribriform DCIS), Ki-67 proliferation index for the invasive cribriform and non-cribriform components separately when feasible, multidisciplinary tumor board histologic classification discussion records, and pathology report revision workflows when initial component percentage estimates are revised after discussion at 1-minute intervals during business hours. Alert immediately — mixed histology documentation platform failures create classification ambiguities that misapply risk stratification and treatment algorithms.
Endocrine Therapy Prescribing and Adherence Monitoring
Monitor aromatase inhibitor prescribing records (anastrozole, letrozole, exemestane with postmenopausal status confirmation), tamoxifen prescribing records for premenopausal women or AI-intolerant patients, prescription refill adherence tracking with 30-day gap flagging and nurse outreach workflow, arthralgia severity assessment and AI switching documentation, hot flash severity and management during tamoxifen, 5-year extended therapy decision documentation (MA.17R and ATLAS discussion records), sequential endocrine therapy documentation (AI-to-AI switching, AI-to-tamoxifen transition), and patient education portal access at 1-minute intervals during business hours. Alert immediately — adherence monitoring failures disrupt the multi-year endocrine therapy compliance tracking that is the primary recurrence prevention strategy for cribriform carcinoma.
Surveillance Mammography and Breast MRI Interval Scheduling
Monitor annual mammography scheduling (ipsilateral and contralateral breast), breast MRI scheduling for higher-risk patients (dense breast tissue, augmented breasts, prior close margins, BRCA carrier status), imaging result routing from radiology to oncology with BI-RADS classification and comparison to prior surveillance images, surveillance visit scheduling (clinical breast exam every 3–6 months for years 1–3, then annually), surveillance continuity across the 5–10 year endocrine therapy arc and beyond, late recurrence detection workflow (routing any suspicious imaging finding to the multidisciplinary team for biopsy and management planning), and survivorship record continuity at 2-minute intervals during business hours. Alert at sustained outage — surveillance scheduling failures allow annual imaging lapses in a patient population whose long-term excellent survival creates an extended follow-up obligation.
DEXA Bone Density and Aromatase Inhibitor Monitoring
Monitor DEXA bone density scan scheduling (baseline and every 1–2 years during AI therapy), DEXA result routing to oncologist with T-score and FRAX calculation, bisphosphonate and denosumab prescribing triggers at T-score ≤−2.0 or T-score −1.0 to −2.0 with additional risk factors, calcium and vitamin D supplementation prescribing documentation, endocrinology referral for complex osteoporosis management, and cardiovascular risk monitoring during long-term estrogen suppression (lipid panels, blood pressure during tamoxifen, thromboembolic event documentation) at 1-minute intervals during clinical hours. Alert immediately — bone density platform failures allow aromatase inhibitor-induced osteoporosis to progress undetected during the decade-long endocrine therapy course.
Authentication and Multidisciplinary Team Access
Monitor authentication at 1-minute intervals, 24/7. Cribriform carcinoma programs coordinate across breast surgery, medical oncology, radiation oncology, surgical pathology (histologic subtype classification), molecular pathology (Oncotype DX), radiology, genetic counseling, endocrinology (bone density), cardiology (cardiovascular risk during long-term estrogen suppression), pharmacy, and primary care — authentication failures simultaneously block the multidisciplinary team whose mixed histology classification and genomic assay result routing depend on authentication-gated platforms.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, genomic assay result routing systems, pathology reporting platforms, endocrine therapy prescribing platforms, DEXA scheduling systems, and surveillance imaging scheduling platforms. Certificate errors disrupt the Oncotype DX result delivery and histologic classification communication that cribriform carcinoma's risk stratification demands.
HIPAA and Oncology Data Privacy Considerations
Cribriform carcinoma of the breast technology platforms handle sensitive PHI including Oncotype DX Recurrence Score records (genomic PHI with prognostic and insurance implications), detailed pathology reports documenting mixed histologic component percentages, long-term endocrine therapy prescribing and adherence records, DEXA bone density records, and breast cancer diagnosis and surveillance records spanning a decade-plus follow-up arc. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components.
For platforms managing Oncotype DX Recurrence Score records and mixed histology pathology documentation — where genomic prognostic scores and detailed histologic classification together determine chemotherapy decisions and could affect insurance or clinical trial eligibility — privacy protections must reflect the combined genomic and pathologic sensitivity of these integrated records. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for oncology programs managing cribriform carcinoma's intersection of genomic assay, histologic subtype, endocrine therapy adherence, and long-term survivorship PHI.
Alerting Strategy for Cribriform Carcinoma of the Breast Tech Platforms
Immediate alerting for genomic result routing: Oncotype DX result delivery platforms during active result routing windows, where delayed RS score delivery prolongs the chemotherapy decision uncertainty for mixed cribriform carcinomas with intermediate RS scores.
Immediate business-hours alert: Endocrine therapy prescribing and adherence platforms, where prescription gaps represent non-adherence events requiring clinical outreach during the multi-year treatment arc.
Immediate alerting for histologic classification: Mixed histology documentation platforms during active multidisciplinary tumor board discussions, where pathology report availability determines risk stratification accuracy.
Immediate alerting during DEXA review windows: Bone density result routing and bisphosphonate prescribing platforms when DEXA results are delivered and intervention thresholds require assessment.
Sustained-failure alert (10–15 minutes): Surveillance mammography and MRI scheduling platforms and survivorship coordination systems.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms cribriform carcinoma platform availability from the geographies where high-volume breast cancer centers with molecular pathology capabilities, multidisciplinary tumor boards with cribriform histology expertise, and long-term endocrine therapy management programs concentrate — important for a rare cancer whose mixed histology documentation complexity requires specialized pathology platform reliability.
Status Page for Cribriform Carcinoma Care Team Communication
A real-time status page gives medical oncologists integrating genomic assay results with histologic subtype context, breast surgeons performing lumpectomy, radiation oncologists completing adjuvant planning, pathologists classifying pure versus mixed cribriform components, molecular pathologists routing Oncotype DX results, radiologists reading surveillance imaging, endocrinologists managing aromatase inhibitor-induced bone loss, and survivorship coordinators managing extended follow-up schedules immediate platform visibility. During a genomic assay result routing platform outage when the multidisciplinary tumor board is reviewing the RS result for a patient with mixed cribriform carcinoma containing 25% Grade 2 ductal NOS components — where the oncologist must integrate the intermediate RS score with the histologic subtype documentation to make the individualized chemotherapy recommendation — a status page enables immediate contingency protocol activation so that the RS result can be communicated by telephone and the histologic classification documentation retrieved from the pathology system independently.
Include the status page URL in Oncotype DX result delivery downtime procedures, mixed histology documentation emergency workflows, endocrine therapy prescribing fallback protocols, and DEXA scheduling emergency procedures.
Vigilmon Setup for Cribriform Carcinoma of the Breast Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Oncotype DX / genomic assay result routing | 1 min | Slack + PagerDuty (result delivery windows) | | Mixed histology pathology documentation | 1 min | Slack + PagerDuty (business hours) | | Endocrine therapy prescribing / adherence tracking | 1 min | Slack + PagerDuty (business hours) | | DEXA scheduling / bone density monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Bisphosphonate / denosumab prescribing triggers | 1 min | Slack + PagerDuty (clinical hours) | | Aromatase inhibitor arthralgia / switching documentation | 2 min | Slack (business hours) | | Extended endocrine therapy decision (yr 5) | 2 min | Slack (business hours) | | Annual surveillance mammography scheduling | 2 min | Slack (business hours) | | Breast MRI surveillance scheduling | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure Oncotype DX and genomic assay result routing platforms with immediate alerting during result delivery windows
- Add mixed histology pathology documentation platforms with immediate alerting during multidisciplinary tumor board windows
- Configure endocrine therapy prescribing and adherence tracking platforms with immediate business-hours alerting for refill gaps
- Add DEXA bone density scheduling and result routing platforms with immediate clinical-hours alerting for T-score threshold events
- Configure bisphosphonate and denosumab prescribing trigger platforms with immediate alerting when bone density thresholds are crossed
- Add aromatase inhibitor arthralgia documentation and AI switching platforms with sustained-failure alerting
- Configure annual surveillance mammography and breast MRI scheduling with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, pathology, pharmacy, imaging, and survivorship domains
- Add the status page URL to genomic assay downtime procedures, mixed histology documentation emergency workflows, endocrine therapy prescribing fallback protocols, and DEXA scheduling emergency procedures
Conclusion
Cribriform carcinoma of the breast technology platforms are embedded in clinical decisions where mixed histology documentation and Oncotype DX result routing platform availability during the period when a 64-year-old woman's surgical pathology report has documented a 2.1 cm invasive carcinoma with 65% cribriform pattern and 35% invasive ductal carcinoma NOS with Grade 2 nuclear features — where the pathologist's structured percentage-by-component documentation platform must route the mixed cribriform classification to the medical oncologist alongside the Oncotype DX RS result returned that same day showing RS 22, and where the oncologist must integrate the intermediate RS, the mixed cribriform histology with 35% Grade 2 ductal NOS component, and the patient's premenopausal status at age 51 to make the individualized chemotherapy recommendation per TAILORx subgroup evidence — cannot be disrupted by histology documentation or RS result routing platform failures on the day when the two data streams must integrate to generate the treatment recommendation; where endocrine therapy adherence platform availability during the period when a 59-year-old woman with pure cribriform carcinoma has been on letrozole for 3 years and 8 months — where the adherence platform tracks her monthly refill pattern, flags her 35-day refill gap in month 44 of therapy, routes the non-adherence flag to the oncology nurse for outreach within 48 hours, and the nurse's call reveals that the patient stopped letrozole because of worsening arthralgias and fatigue she had not reported at her last quarterly visit, enabling the nurse to schedule an urgent oncology visit for aromatase inhibitor switching to exemestane and arthralgia management before the patient's non-adherence extends to 60 or 90 days — cannot be disrupted by adherence monitoring platform failures at the 44th-month mark when a non-adherent patient's endocrine therapy arc is at risk of truncation that forfeits the remaining 16 months of the 5-year course; and where DEXA bone density platform availability during the period when the same patient's year-2 on-letrozole DEXA result shows a T-score at the hip of −2.3 — where the platform must route the T-score result to the oncologist the same day to trigger bisphosphonate prescribing, where the alendronate prescription generated by the threshold-crossing T-score result protects the patient's bone mineral density during the 2 remaining years of letrozole before her extended therapy decision, and where a 3-day delay in the DEXA result routing means 3 days of avoidable fracture-risk elevation at a threshold T-score — cannot be disrupted by DEXA result routing platform delays at the intervention threshold detection point. A histology documentation platform that fails when the tumor board needs the cribriform component percentages to contextualize an intermediate RS result, an adherence monitoring platform that misses the month-44 refill gap at the window when endocrine therapy switching preserves course completion, a DEXA result routing platform that delays the bisphosphonate prescribing trigger at the threshold T-score — these are not IT incidents. They are clinical disruptions in the management of a breast cancer subtype whose excellent prognosis depends on the histologic classification precision, genomic assay result integration, endocrine therapy adherence monitoring, and bone density surveillance infrastructure that platform reliability must sustain.
Uptime monitoring gives cribriform carcinoma of the breast tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to breast oncology programs, pathology services, genomic assay laboratories, bone density monitoring services, and compliance auditors that platform operational reliability matches the mixed histology documentation precision, genomic risk stratification complexity, endocrine therapy adherence monitoring duration, and bone density surveillance obligations of modern cribriform carcinoma of the breast care.
Start monitoring your cribriform carcinoma of the breast care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #cribriformcarcinoma #breastcancer #OncotypeDX #recurrenceScore #mixedhistology #aromataseinhibitor #tamoxifen #endocrinetherapy #bonedensity #DEXA #bisphosphonate #lowgradebreastcancer #cancertech #healthtech #digitalhealth #uptime #sre #HIPAA